Market Overview

Ironwood's Pipeline Needs Work, Analyst Downgrades


Analysts at JPMorgan no longer hold a bullish view on Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) after the company released top-line results from a phase 2b trial called IW-3718. The firm's Anupam Rama downgraded Ironwood's stock from Overweight to Neutral with a price target lowered from $20 to $19.

Ironwood's valuation should compose of two entities, the analyst explained. First the company's commercial franchise (Linzess and Zurampic/Duzallo) is worth $17 to $18 per share with upside coming from new products in the pipeline. The problem is that the company's pipeline only has "some value" and large value creation will take time.

"The unmet need in the refractory GERD is clear; however, the phase 2b data, while overall trending in the right direction, does not fully de-risk the phase 3 program, with many questions left open (high placebo rate in a refractory population, clinical meaningfulness of IW-3718 treatment effect, baseline characteristics, degree of dose response in phase 2b and dose optimization into the phase 3, etc)," the analyst wrote.

Finally, Ironwood's IW-3718 phase 2b results shows that investors need to wait "an even longer" time for appreciation in the stock, Rama continued. On top of that, it will also take "definitively compelling clinical data" from the sGC platform for any improvement in sentiment.

Related Links:

The Market In 5 Minutes

10 Stocks To Watch For July 21, 2017

Latest Ratings for IRWD

Jul 2019AssumesNeutral
Mar 2019UpgradesUnderweightEqual-Weight
Feb 2019UpgradesSellNeutral

View More Analyst Ratings for IRWD
View the Latest Analyst Ratings

Posted-In: Anupam Rama GERD Ironwood LinzessAnalyst Color Downgrades Price Target Analyst Ratings


Related Articles (IRWD)

View Comments and Join the Discussion!

Latest Ratings

WENMorgan StanleyMaintains22.0
XGNCantor FitzgeraldInitiates Coverage On18.0
LOOPRoth CapitalInitiates Coverage On14.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Capital One Issues EPS Guidance For The First Time In Recent Memory

No Reason To Believe Intuitive Surgical's Momentum Will Stop Now